Publication | Closed Access

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial

Gastrointestinal OncologyMedicineImmunologyPathologyAdvanced GastricCancer TreatmentOncologyRadiation OncologyGastro-oesophageal Junction CancerCancer Research